Akero Therapeutics Inc $ 31.06 1.17 (3.91%)
Volume:
182,194
Avg Vol (1m):
288,048
Market Cap $:
1.08 Bil
Enterprise Value $:
788.46 Mil
P/E (TTM):
0.00
P/B:
3.69
Current and historical daily P/E ratio for AKRO (Akero Therapeutics Inc) from 2019 to Jan 23 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Akero Therapeutics stock (AKRO) PE ratio as of Jan 23 2021 is 0.
More Details
Akero Therapeutics PE Ratio (TTM) Chart
EMBED
Akero Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Total 418
- 1
- 2
- 3
- 4
- 5
| Akero Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2021-01-23 | 0.0 | 2020-11-23 | 0.0 |
| 2021-01-22 | 0.0 | 2020-11-20 | 0.0 |
| 2021-01-21 | 0.0 | 2020-11-19 | 0.0 |
| 2021-01-20 | 0.0 | 2020-11-18 | 0.0 |
| 2021-01-19 | 0.0 | 2020-11-17 | 0.0 |
| 2021-01-18 | 0.0 | 2020-11-16 | 0.0 |
| 2021-01-15 | 0.0 | 2020-11-13 | 0.0 |
| 2021-01-14 | 0.0 | 2020-11-12 | 0.0 |
| 2021-01-13 | 0.0 | 2020-11-11 | 0.0 |
| 2021-01-12 | 0.0 | 2020-11-10 | 0.0 |
| 2021-01-11 | 0.0 | 2020-11-09 | 0.0 |
| 2021-01-08 | 0.0 | 2020-11-06 | 0.0 |
| 2021-01-07 | 0.0 | 2020-11-05 | 0.0 |
| 2021-01-06 | 0.0 | 2020-11-04 | 0.0 |
| 2021-01-05 | 0.0 | 2020-11-03 | 0.0 |
| 2021-01-04 | 0.0 | 2020-11-02 | 0.0 |
| 2021-01-01 | 0.0 | 2020-10-30 | 0.0 |
| 2020-12-31 | 0.0 | 2020-10-29 | 0.0 |
| 2020-12-30 | 0.0 | 2020-10-28 | 0.0 |
| 2020-12-29 | 0.0 | 2020-10-27 | 0.0 |
| 2020-12-28 | 0.0 | 2020-10-26 | 0.0 |
| 2020-12-25 | 0.0 | 2020-10-23 | 0.0 |
| 2020-12-24 | 0.0 | 2020-10-22 | 0.0 |
| 2020-12-23 | 0.0 | 2020-10-21 | 0.0 |
| 2020-12-22 | 0.0 | 2020-10-20 | 0.0 |
| 2020-12-21 | 0.0 | 2020-10-19 | 0.0 |
| 2020-12-18 | 0.0 | 2020-10-16 | 0.0 |
| 2020-12-17 | 0.0 | 2020-10-15 | 0.0 |
| 2020-12-16 | 0.0 | 2020-10-14 | 0.0 |
| 2020-12-15 | 0.0 | 2020-10-13 | 0.0 |
| 2020-12-14 | 0.0 | 2020-10-12 | 0.0 |
| 2020-12-11 | 0.0 | 2020-10-09 | 0.0 |
| 2020-12-10 | 0.0 | 2020-10-08 | 0.0 |
| 2020-12-09 | 0.0 | 2020-10-07 | 0.0 |
| 2020-12-08 | 0.0 | 2020-10-06 | 0.0 |
| 2020-12-07 | 0.0 | 2020-10-05 | 0.0 |
| 2020-12-04 | 0.0 | 2020-10-02 | 0.0 |
| 2020-12-03 | 0.0 | 2020-10-01 | 0.0 |
| 2020-12-02 | 0.0 | 2020-09-30 | 0.0 |
| 2020-12-01 | 0.0 | 2020-09-29 | 0.0 |
| 2020-11-30 | 0.0 | 2020-09-28 | 0.0 |
| 2020-11-27 | 0.0 | 2020-09-25 | 0.0 |
| 2020-11-26 | 0.0 | 2020-09-24 | 0.0 |
| 2020-11-25 | 0.0 | 2020-09-23 | 0.0 |
| 2020-11-24 | 0.0 | 2020-09-22 | 0.0 |
Akero Therapeutics PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Compare
NAS:CDXS
NAS:AVRO
NAS:KALA
NAS:FIXX
NYSE:KDMN
NAS:GTHX
NAS:MTEM
NAS:ZIOP
NAS:OYST
NAS:ADAP
OCSE:NOVO B
ASX:CSL
NAS:VRTX
NAS:REGN
XKRX:207940
NAS:SGEN
NAS:MRNA
NAS:ALXN
XKRX:068270
NAS:INCY
Address
170 Harbor Way, 3rd Floor, South San Francisco, CA, USA, 94080
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate AKR-001 is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.